Analysts think TARA stock price could increase by 585%
Jun 08, 2025, 11:25 AM
-15.82%
What does TARA do
Protara Therapeutics, based in New York, develops treatments for rare diseases and is conducting Phase II trials for its lead candidate, TARA-002, in non-muscle invasive bladder cancer and lymphatic malformations. The company also works on IV Choline Chloride for patients needing parenteral nutrition.
8 analysts think TARA stock price will increase by 585.07%. The current median analyst target is $22.95 compared to a current stock price of $3.35. The lowest analysts target is $12.12 and the highest analyst target is $31.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
